

1 **Secondary pneumonia in critically ill ventilated patients with COVID-19**

2

3 Mailis Maes^{1*}, Ellen Higginson^{1*}, Joana Pereira-Dias^{1*}, Martin Curran², Surendra Parmar²,

4 Fahad Khokhar¹, Delphine Cuchet-Lourenço³, Janine Lux³, Sapna Sharma-Hajela⁴, Benjamin Ravenhill⁴,

5 Razeen Mahroof⁴, Amelia Solderholm¹, Sally Forrest¹, Sushmita Sridhar^{1,5}, Nicholas Brown², Stephen Baker¹,

6 Vilas Navapurkar⁴, Gordon Dougan¹, Josefin Bartholdson Scott¹, Andrew Conway-Morris^{3,4#}

7

81 ¹ Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine,

9 University of Cambridge, Cambridge, United Kingdom

10 ²Public Health England, Clinical Microbiology and Public Health Laboratory, Addenbrookes Hospital,

11 Cambridge, United Kingdom

122 ³Department of Medicine, University of Cambridge, Cambridge, United Kingdom

133 ⁴John Farman ICU, Addenbrookes Hospital, Cambridge, United Kingdom

144 ⁵ Wellcome Sanger Institute, Hinxton, United Kingdom

15

16 *Contributed equally to the paper

17 # Corresponding author

18 Andrew Conway Morris

19 Division of Anaesthesia

20 Department of Medicine

21 Level 4, Addenbrooke's Hospital

22 Hills Road

23 Cambridge

24 CB2 0QQ

25 Email: ac926@cam.ac.uk

26 Phone: +44 (0)1223 217889

27

28

29 Running title: Secondary pneumonia in COVID-19 patients.

30 Word count: 2630

31

32 Author statement

33 We studied the microbial composition and diagnostic microbiology results of bronchoalveolar lavage
34 (BAL) samples taken from adult COVID-19 patients and COVID-19 negative patients receiving
35 artificial ventilation in a teaching hospital ICU. We observed that although COVID-19 patients had a
36 greater incidence of VAP, the associated causative pathogens were similar in both groups.

37

38 Keywords:

39 COVID-19, SARS-CoV-2, coinfections, microarray, VAP, ICU.

40

41 **Abstract**

42 **Background** Pandemic COVID-19 caused by the coronavirus SARS-CoV-2 has a high incidence of
43 patients with severe acute respiratory syndrome (SARS). Many of these patients require admission to
44 an intensive care unit (ICU) for invasive artificial ventilation and are at significant risk of developing
45 a secondary, ventilator-associated pneumonia (VAP).

46 **Objectives** To study the incidence of VAP, as well as differences in secondary infections, and
47 bacterial lung microbiome composition of ventilated COVID-19 and non-COVID-19 patients.

48 **Methods** In this prospective observational study, we compared the incidence of VAP and secondary
49 infections using a combination of a TaqMan multi-pathogen array and microbial culture. In addition,
50 we determined the lung microbiome composition using 16S RNA analysis. The study involved
51 eighteen COVID-19 and seven non-COVID-19 patients receiving invasive ventilation in three ICUs
52 located in a single University teaching hospital between April 13th 2020 and May 7th 2020.

53 **Results** We observed a higher percentage of confirmed VAP in COVID-19 patients. However, there
54 was no statistical difference in the detected organisms or pulmonary microbiome when compared to
55 non-COVID-19 patients.

56 **Conclusion** COVID-19 makes people more susceptible to developing VAP, partly but not entirely
57 due to the increased duration of ventilation. The pulmonary dysbiosis caused by COVID-19, and the

58 array of secondary infections observed are similar to that seen in critically ill patients ventilated for

59 other reasons.

60

61 Abstract word count: 209

62

63

64 **Background**

65 Pandemic COVID-19 is associated with a high number of patients suffering from severe acute
66 respiratory syndrome (SARS). Such patients can spend significant periods of time in intensive care
67 units (ICU), with >80% of patients admitted to ICU requiring invasive mechanical ventilation [1,2].
68 Critically ill patients are at high risk of nosocomial pneumonia, especially when ventilated [3]. The
69 reasons for this includes breach of natural defences by invasive devices [4], sedation and impairment
70 of coughing and mucociliary clearance, and the immunoparetic effects of critical illness [5,6]. Early
71 reports indicated that critically ill patients infected with SARS-CoV-2 had a high prevalence of
72 nosocomial pneumonia, especially ventilator-associated pneumonia (VAP) [7]. This is likely
73 influenced by the widespread use of corticosteroids and empiric immunosuppressive medication
74 together with increased prevalence of co-morbid conditions [7] and the prolonged duration of
75 artificial ventilation [2].

76
77 The management of critically ill patients with COVID-19 requires the identification, or exclusion, of
78 bacterial, viral or fungal pathogens which may be present as co-infections on presentation or arise
79 later in the course of the disease. Ventilator-associated pneumonia (VAP) can be challenging to
80 diagnose as a range of non-infectious diseases may mimic the clinical picture of radiographic
81 infiltrates, systemic inflammation and impaired oxygenation that typifies VAP [8]. To limit
82 overdiagnosis and facilitate appropriate antimicrobial therapy in VAP, most centres use culture- based
83 approaches [9,10]. However, molecular tests to detect multiple pathogens (viruses and bacteria) are
84 becoming more accessible and may further reduce unnecessary antimicrobial therapy [11].
85 Additionally, the choice of diagnostic sample is critical and directed bronchoscopy can limit
86 contamination from the proximal airway [12]. An observation that the rate of VAP amongst patients
87 with COVID-19 appeared to be higher than our background rate led to the institution of a minimally-
88 aerosol generating bronchoscopic sampling procedure to seek to minimise over-diagnosis inherent in
89 endo-tracheal aspirate-based sampling [12].

90

91 In this study, we aimed to identify and compare the distribution of secondary infections and VAP in
92 critically ill ventilated COVID-19 patients against ventilated non-SARS-CoV-2 infected patients. We
93 performed conventional microbiology, multi-pathogen molecular testing, and assessed the
94 composition of the bacterial lung microbiome in bronchoalveolar lavage (BAL) samples of COVID-
95 19 positive and COVID-19 negative patients in the same hospital over a certain time period.

96

97 **Materials and methods**

98

99 *Setting and study design*

100 This study was performed in three adult ICUs in Addenbrooke's Hospital, Cambridge, UK,
101 consisting of a liver/general unit, neurotrauma unit and a surge capacity COVID unit. Units had
102 routinely audited ventilator bundles in place, which included sub-glottic suction tubes, mandated
103 twice daily oral hygiene with fluoride toothpaste, daily sedation holds and head of bed elevation.
104 Patients from April 13th to May 7th were included in the study if the treating clinician was
105 undertaking BAL for the diagnosis of respiratory infection in a ventilated patient. All patients had X-
106 ray infiltrates and features of systemic inflammation (raised white cell count, temperature >38°C,
107 raised C-reactive protein and/or raised serum pro-calcitonin levels).

108

109 BALs were conducted in accordance with a modified unit protocol designed to minimise aerosol
110 generation. Briefly, staff members wearing appropriate personal protective equipment (PPE) inserted
111 a pre-loaded bronchoscope through an endotracheal tube catheter mount. The bronchoscope was
112 wedged in a sub-segmental bronchus corresponding to the region of maximal infiltrate on plain
113 radiography. Up to 200ml of saline was instilled and aspirated.

114

115 *Diagnostics*

116 Samples for routine microbiology were processed according to the UK Standards for Microbiology
117 Investigations [13]. Any significant growth with a CFU of >10⁴/mL was identified by MALDI-ToF
118 mass spectrometry.

119

120 *RNA/DNA extraction and SARS-CoV-2 qPCR*

121 500µl of BAL was subjected to RNA/DNA extraction following an existing method [14]. Viscous
122 samples were first treated with 10% v/v mucolysin, before 500µl lysis buffer (25mM Tris-HCL+ 4M
123 Guanidine thiocyanate with 0.5% b-mercaptoethanol) and glass beads were added to each sample.
124 Tubes were vortexed, and 100% analytical grade ethanol was added to a final concentration of 50%.
125 After a 10 min incubation, 860µl of lysis buffer (containing MS2 as an internal extraction and
126 amplification control) was added. This was then run over an RNA spin column as previously
127 described [14]. SARS-CoV-2 specific real-time RT-PCR was performed and interpreted as
128 previously described [14].

129

130 *TaqMan multi-pathogen array*

131 Custom designed TaqMan Array Cards (TAC; Thermo Fisher Scientific) targeting 52 different
132 common respiratory pathogens, were used to test for secondary infections as previously described
133 [15] with modifications. Fifty microlitres of extracted nucleic acid was used in a 200 µl final reaction
134 volume with TaqMan™ Fast Virus 1-step Master Mix (Thermo Fisher Scientific), and cards were run
135 on the QuantStudio 7 Flex platform (Thermo Fisher Scientific) as per the manufacturer's instructions.
136 Detection of a clear exponential amplification curve with a Cycles to Threshold (CT) value ≤ 32 for
137 any single gene target was reported as a positive result for the relevant pathogen. In those patients
138 who had BALs obtained more than once, new pathogens identified in later samples were added to the
139 results of the initial array.

140

141 *VAP diagnosis*

142 The definition of VAP was adapted from the European Centre for Disease Control criteria [16]. VAP
143 was determined to be present in those patients with clinical evidence of pulmonary inflammation,
144 radiographic evidence of lung infiltrates and detection of significant amounts of pathogenic bacterial
145 or fungal species. Clinically significant amounts of pathogen were defined as those detected at a CT

146 value ≤ 32 and/ or microbial growth on culture of $\geq 10^4$ CFU/ml. Low lung pathogenicity organisms
147 (*Enterococcus spp.*, *Candida albicans*, non-pneumococcal *Streptococci* and coagulase negative
148 *Staphylococci*) were reported but not considered a component of VAP [17]. *Herpesviridae* (Herpes
149 simplex, cytomegalovirus and Epstein-Barr virus) were reported but were considered to be
150 reactivations and not considered a component of VAP [18].

151

152 *16S Nanopore sequencing*

153 Extracted nucleic acids were concentrated using AMPure XP beads (Beckman Coulter) and 16S DNA
154 libraries prepared using the 16S Barcoding Kit SQK-16S024 (Oxford Nanopore Technologies) as per
155 the manufacturer's instructions. Final DNA libraries were loaded onto FLO-MIN106D R9.4.1 flow
156 cells and sequencing was performed on a GridION Mk1 for ~36 hours with high accuracy basecalling
157 enabled. The resulting fastq files were de-multiplexed with guppy_barcode v3.6.0 using the --
158 require_barcode_both_ends and --trim_barcode flags. Porechop v0.2.4
159 (<https://github.com/rrwick/Porechop>) was used to trim adapter and barcode sequences and Nanofilt
160 v2.6.0 (De Coster, et. al., 2018) was used to filter the reads by length, 1,400 – 1,600 bps and a quality
161 score of 10. Reads were classified against the Silva 132 99% OTUs 16S database using Kraken2 [19].
162 Microbial diversity analyses were carried out in R using packages vegan [20] and metacoder [21].

163

164 **Results**

165 During the COVID-19 outbreak we have used a combination of TaqMan multi-pathogen array
166 and conventional microbial culture to investigate secondary infections associated with patients
167 undergoing ventilation. In our ICU, VAP was suspected in 82% of ventilated patients with COVID-19
168 and confirmed by culture or TAC in 49% of these patients, giving an incident density of 26 per 1000
169 ventilator days for confirmed VAP and 52 per 1000 ventilator days for suspected VAP. We report in
170 more detail the diagnoses made from protected lower respiratory samples analysed by these combined
171 culture-based and molecular techniques.

172

173 34 BAL samples were taken from 25 patients, of which the clinical and demographic data are
174 summarized in Table 1; five patients were sampled on two occasions and two patients sampled on
175 three occasions over the study period. Nineteen of these samples were SARS-CoV-2 positive by RT-
176 PCR, with a mean CT of 28.3. Fifteen samples tested negative for SARS-CoV-2; however, six of
177 these samples came from patients previously diagnosed with COVID-19 by RT-PCR (Table 2).

178

179 Amongst the 14 patients with a SARS-CoV-2 positive RT-PCR at time of sampling, nine were
180 confirmed to have VAP on the basis of clinical features and detection of a lung pathogen at a $CT \leq 32$
181 or by microbial culture $>10^4$ CFU/ml. Of these, one patient incurred two episodes of VAP, first with
182 *S. aureus* and later with *S. maltophilia*. Of the seven patients without COVID-19, four developed
183 confirmed VAP. Three of the four patients previously diagnosed with COVID-19 but with negative
184 SARS-CoV-2 RT-PCR at the time of sampling also were confirmed as VAP. (The co-infecting
185 organisms are shown in Table 2).

186

187 Notably, there was no significant difference in the concentration (CT) or distribution of organisms
188 between the COVID-19 positive and negative patients. Although not classed as VAP here, a number
189 of organisms (*Enterococcus spp.*, *Candida albicans*, non-pneumococcal *Streptococci*) and reactivated
190 viruses (Herpes simplex), normally regarded as being of low pathogenic potential, were detected in
191 patients (Table 2). In some cases, these were detected alongside classical lung pathogens, whereas in
192 other patients they were the sole organisms detected. There was no clear difference in the prevalence
193 of low-pathogenicity organisms between patients positive or negative for SARS-CoV-2. The mean
194 number of organisms detected by TAC in the COVID positive patients was 1.8 organisms/patient
195 (range 0 - 5), whereas the equivalent number in the COVID negative group was 1.1 organisms/patient
196 (range 0 - 3).

197

198 To investigate changes in the lung microbiota in the COVID-19 positive and negative patients we
199 performed 16S rRNA sequencing on a subset of BAL samples. In general, bacteria detected by TAC

200 or conventional microbiology were abundantly identified in samples by 16S sequencing (Figure 1).
201 When comparing COVID-19 positive to COVID-19 negative patients, there was no specific taxon that
202 was more prevalent in either group. Additionally, the microbiomes of COVID-19 positive patients
203 were not significantly different in either the species richness (alpha diversity) or the microbial
204 composition (beta diversity) to those of COVID-19 negative patients.

205

206 To investigate changes in the microbiota over the course of infection, we next looked at the microbial
207 composition of BAL samples in individual patients over time. Two patients diagnosed with VAP
208 (patients 1 and 24) showed decreasing species richness over time, as the bacterial pathogen implicated
209 in the illness became the predominant microbe present. For patient 6, the microbial composition
210 shifted significantly over time, as *Enterococcus* took over from *Staphylococcus* as the most
211 predominant pathogen. The microbiome composition of patient 24, who was both VAP and COVID-
212 19 negative, was largely stable over time. In general, the lung microbiomes of patients who did not
213 have VAP at the time of sampling (sample 1 from patient 14 and both samples from patient 24) were
214 more diverse than samples from patients who had been diagnosed with VAP.

215

216 **Discussion**

217 COVID-19 is a very new disease in the human population and this has led to an increase in the
218 number of patients in need of active sustained ventilation, which in turn introduces an increased risk
219 of VAP. COVID-19 can present in many different severe manifestations and reports of co-infections
220 vary [22,7]. However, often these reports suffer from a lack of clarity around the severity of illness,
221 location of patients (critical care vs non-critical care), timing of sampling relative to onset of disease
222 and, where applicable, the use of mechanical ventilation [22]. Here, we report on the most severely
223 affected COVID-19 patients who required clinical management on an ICU with mechanical
224 ventilation. We found a high incident density of confirmed (26/1000 ventilator days) and suspected
225 (52/1000 ventilator days) VAP in COVID-19 patients. This is greater than the previously reported
226 rates from units with similar admission profiles and use of ventilator bundles, where incident densities
227 were 6-14/1000 ventilator days for confirmed and 12-32/1000 ventilator days for suspected VAP [23].

228 Although incident density can correct for duration of ventilation to some extent, it is imperfect and
229 long-staying patients may display different features from shorter staying patients [24]. However, even
230 when compared to reports of patients staying for >14 days [23], incident density for COVID-19
231 patients remains high.

232

233 At the lung microbiome level, we observed no difference in the composition of organisms between
234 COVID-19 positive and COVID-19 patients who developed VAP. Similarly, the causative pathogens
235 identified using molecular and culture methods, were comparable in both the COVID-19 positive and
236 negative patients. Reassuringly, antibiotic susceptibility of the causative pathogens was similar in the
237 two groups (data not shown) and this meant that conventional antimicrobial regimens could be used.
238 We did detect by TAC assay *Aspergillus fumigatus* in one patients, with supportive clinical and
239 radiographic features, suggesting genuine fungal infection. This is notable as there is increasing
240 recognition of fungal infections amongst patients with viral pneumonitides [25]. Our data support the
241 concept that COVID-19, in common with other critical illness syndromes requiring mechanical
242 ventilation, induces a pulmonary dysbiosis, leading to overgrowth of enteric and respiratory
243 organisms, many of which are of low pathogenic potential[26,27]. These observations likely reflect
244 intercurrent antimicrobial therapy and a degree of immunoparesis which is also observed in other
245 critical illness states. Systemic inflammation, including activation of complement and release of C5a
246 is a hallmark of severe COVID-19 [7, 28], with excessive C5a release being a key driver of innate
247 immune dysfunction in critically ill patients and predictor of subsequent infections [23,5].

248

249 Studies reporting on VAP in COVID-19 patients are limited and have not reported the
250 microbiological or diagnostic details of the case [7]; however, it has been suggested that bacterial
251 pneumonia may be facilitated by the use of corticosteroids and empiric immunosuppressive
252 medication. In our setting these medications are not commonly used, yet there remains a high
253 prevalence of bacterial VAP in COVID-19 patients. Although VAP in COVID-19 may present
254 problems of quantity, we did not find evidence in this report of a qualitative difference. Indeed, the
255 microbial profiles of ventilated patients with active SARS-CoV-2, those who had cleared SARS-CoV-

256 2 and those who never had the viral infection were similar on both targeted TAC and 16S rRNA
257 sequencing. Our patients demonstrated similar profiles to those reported by other groups investigating
258 the pulmonary microbiome of ventilated patients [26,29]. The factors which lead to pulmonary
259 dysbiosis in critical illness remain incompletely understood, but may include intercurrent antibiotic
260 use, enteric translocation, pulmonary immune dysfunction and altered clearance [30, 27]. We
261 acknowledge the sample size limitations with our observations and suggest larger studies from
262 distinct geographic locations may help fully understand the risk of developing secondary bacterial
263 infections in patients with severe COVID-19.

264

265 **Conclusion**

266 COVID-19 makes people more susceptible to developing VAP, partly but not entirely due to the
267 increased duration of ventilation. The change in lung microbiome and causes of secondary infection
268 are similar to those seen in critically ill patients ventilated for other reasons. Careful sampling of the
269 respiratory tract whilst minimising contamination from the proximal tract, in combination with
270 sensitive diagnostic testing to reduce the risk of false negative cultures will aid antimicrobial
271 optimisation in patients with COVID-19.

272

273 **Ethical approval and consent to participate**

274 The *TaqMan multi-pathogen array* has been adopted as a routine clinical service in our institution
275 following a previous evaluation study. The use of discard samples surplus to that required for clinical
276 testing, and anonymised data review were conducted under the consent waiver granted by Leeds West
277 NHS Research Ethics Committee (ref: 20/YH/0152).

278

279 **Acknowledgments**

280 Our thanks go out to all the ICU clinicians, nurses and physiotherapists who have ensured proper
281 patient care and sample management even in these hard times, as well as to PHE microbiologists for
282 running standard microbiology tests. Furthermore, the authors wish to thank Mark Wills for his help
283 as Biological Safety Officer to ensure we work in a safe environment. We also thank Estée Török and

284 Ian Goodfellow for access to consumables and the GridION for Nanopore sequencing, and Satpal
285 Ubhi for help with clinical management. Finally, we wish to acknowledge our funders the NIHR
286 BRC. In addition we would like to acknowledge the grant awarded by Addenbrooke's Charitable
287 Trust for the initial study of the clinical utility of the TaqMan microarray.

288

289 **Authors contributions**

290 MM- sample processing, data analysis and manuscript writing; EEH- sample processing, data analysis
291 and manuscript writing; JPD-sample processing and manuscript editing; DCL,JL,AS, SF,SS -sample
292 processing; FK- sample processing and data analysis; SSH, BR, RM- VAP surveillance data
293 collection and clinical management MC,SP, NB- diagnostical data analysis; SB manuscript editing;
294 VN conceived study and clinical management: GD- conceived study and manuscript editing; JBS
295 conceived study, sample processing and manuscript editing ; ACM- conceived study, manuscript
296 writing and clinical management.

297

298 **Consent for publication**

299 All authors read and approved the final version for publication.

300

301 **Availability of supporting data**

302 Raw sequencing data is available on <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA642012>

303

304 **Funding**

305 This study was funded by the National Institute for Health Research [Cambridge Biomedical
306 Research Centre at the Cambridge University Hospitals NHS Foundation Trust]. The views expressed
307 are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health
308 and Social Care. Dr Conway Morris is supported by a Clinical Research Career Development
309 Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z).

310

311 **Competing interest**

312 The authors have declared that no competing interests exist.

313

314

315

316

317 References

- 318 1) Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of COVID-19 in New York City.
319 *N Engl J Med*. April 2020:NEJMc2010419.
- 320 2) Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591
321 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
322 *JAMA*. 2020;323(16):1574-1578.
- 323 3) Vincent J-L, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection Among Patients
324 in Intensive Care Units in 2017. *JAMA*. 2020;323(15):1478–10.
- 325 4) Álvarez-Lerma F, Palomar-Martínez M, Sánchez-García M, et al. Prevention of Ventilator-
326 Associated Pneumonia. *Critical Care Medicine*. 2018;46(2):181-188.
- 327 5) Morris AC, Datta D, Shankar-Hari M, et al. Cell-surface signatures of immune dysfunction
328 risk-stratify critically ill patients: INFECT study. *Intensive Care Med*. 2018;44(5):627-635.
- 329 6) Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular
330 dysfunctions to immunotherapy. *Nat Rev Immunol*. 2013;13(12):862-874.
331 doi:10.1038/nri3552.
- 332 7) Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
333 with COVID-19-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. March
334 2020:1-9. doi:10.1016/S0140-6736(20)30566-3.
- 335 8) Meduri GU, Mauldin GL, Wunderink RG, et al. Causes of fever and pulmonary densities in
336 patients with clinical manifestations of ventilator-associated pneumonia. 1994;106(1):221-
337 235.
- 338 9) Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT
339 guidelines for the management of hospital-acquired pneumonia and ventilator-associated
340 pneumonia: *European Respiratory Journal*. 2017;50(3):1700582.
- 341 10) Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired
342 and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious
343 Diseases Society of America and the American Thoracic Society. *Clinical Infectious
344 Diseases*. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353.

- 345 11) Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Morris AC. Antimicrobial-associated
346 harm in critical care: a narrative review. *Intensive Care Med.* January 2020:1-11.
- 347 12) Morris AC, Kefala K, Simpson AJ, et al. Evaluation of the effect of diagnostic methodology
348 on the reported incidence of ventilator-associated pneumonia. *Thorax.* 2009;64(6):516-522.
349 doi:10.1136/thx.2008.110239.
- 350 13) SMI B 57: investigation of bronchoalveolar lavage, sputum and associated specimens
351 [https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-](https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-lavage-sputum-and-associated-specimens)
352 [lavage-sputum-and-associated-specimens](https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-lavage-sputum-and-associated-specimens)
- 353 14) Sushmita Sridhar, Sally Forrest, Iain Kean, et al. A blueprint for the implementation of a
354 validated approach for the detection of SARS-Cov2 in clinical samples in academic facilities,
355 bioRxiv 2020.04.14.041319; doi:<https://doi.org/10.1101/2020.04.14.041319>
- 356 15) SteenselsD, Reynders M Descheemaeker, et al . Clinical evaluation of a multi-parameter
357 customized respiratory TaqMan® array card compared to conventional methods in
358 immunocompromised patients. *Journal of Clinical Virology.* 2015;72:36-41.
- 359 16) Plachouras D, Lepape A, Suetens C. ECDC definitions and methods for the surveillance of
360 healthcare-associated infections in intensive care units. *Intensive Care Med.* October 2018:1-
361 3.
- 362 17) Chastre J, Fagon J-Y. Ventilator-associated pneumonia. *Am J Respir Crit Care Med.*
363 2002;165(7):867-903.
- 364 18) Bruynseels P, Jorens PG, Demey HE, et al. Herpes simplex virus in the respiratory tract of
365 critical care patients: a prospective study. *The Lancet.* 2014;362(9395):1-6.
- 366 19) Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. *Genome Biol.*
367 2019;20(1):257. Published 2019 Nov 28. doi:10.1186/s13059-019-1891-0
- 368 20) Oksanen, J. (2013). Vegan: ecological diversity. *R Project.*
- 369 21) Foster, Z. S., Sharpton, T. J., & Grünwald, N. J. (2017). Metacoder: an R package for
370 visualization and manipulation of community taxonomic diversity data. *PLoS computational*
371 *biology*, 13(2), e1005404.

- 372 22) Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with
373 coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. *Clin Infect Dis*.
374 May 2020.
- 375 23) Morris AC, Hay AW, Swann DG, et al. Reducing ventilator-associated pneumonia in
376 intensive care: Impact of implementing a care bundle. 2011;39(10):2218-2224.
- 377 24) Nelson JE, Cox CE, Hope AA, Carson SS. Chronic critical illness. *Am J Respir Crit Care*
378 *Med*. 2010;182(4):446-454.
- 379 25) Schauwvlieghe A.F.A.D, Rijnders B.J.A, Philips N. et al. Invasive aspergillosis in patients
380 admitted to the intensive care unit with severe influenza: a retrospective cohort study. *Lancet*
381 *Respiratory Medicine* July 2018 DOI:[https://doi.org/10.1016/S2213-2600\(18\)30274-1](https://doi.org/10.1016/S2213-2600(18)30274-1).
- 382 26) Zakharkina T, Martin-Loeches I, Matamoros S, et al. The dynamics of the pulmonary
383 microbiome during mechanical ventilation in the intensive care unit and the association with
384 occurrence of pneumonia. *Thorax*. 2017;72(9):803-810.
- 385 27) Roquilly A, Torres A, Villadangos JA, et al. Pathophysiological role of respiratory dysbiosis
386 in hospital-acquired pneumonia. *The Lancet Respiratory Medicine*. 2019;7(8):710-720.
387 doi:10.1016/S2213-2600(19)30140-7.
- 388 28) Gao T, Hu M, Zhang X, et al. Highly pathogenic coronavirus N protein aggravates lung
389 injury by MASP-2-mediated complement over-activation. *medrxiv.org*
390 doi:10.1101/2020.03.29.20041962.
- 391 29) Dickson RP, Singer BH, Newstead MW, et al. Enrichment of the lung microbiome with gut
392 bacteria in sepsis and the acute respiratory distress syndrome. *Nat Microbiol*.
393 2016;1(10):16113.
- 394 30) Dickson RP, Huffnagle GB. The Lung Microbiome: New Principles for Respiratory
395 Bacteriology in Health and Disease. Goldman WE, ed. *PLoS Pathogens*.
396 2015;11(7):e1004923-e1004925.
- 397 31) Jacobs F, Denis O et al. Clinical evaluation of a multi-parameter customized respiratory
398 TaqMan® array card compared to conventional methods in immunocompromised patients.
399 *Journal of Clinical Virology*. 2015;72:36-41.

400 32) Browne E, Hellyer TP, Baudouin SV, et al. A national survey of the diagnosis and
401 management of suspected ventilator-associated pneumonia. *BMJ Open Resp Res.*
402 2014;1(1):e000066.
403
404

405 Figure Legends

406

407 Figure 1 Microbial composition of BAL samples from SARS-CoV-2 positive and negative patients.

408 Bacterial 16S genes were sequenced and classified to the genus level using Kraken2. The percent of

409 reads mapping to each genus is shown for individual samples from each patient (A), and longitudinal

410 samples (1, 2 or 3) from individual patients (B, C, D, E). Individuals were classified as either COVID-

411 19 negative, COVID-19 positive, or recovering (previously diagnosed with COVID-19 but SARS-

412 CoV-2 negative at time of sample).

413

414 Tables

415 Table 1. Clinical and demographic features of reported population.

Characteristic	
Median age (range)	57 (31-73)
Female n(%)	9 (36%)
Antibiotics at time of bronchoscopy n(%)	24 (96%)
Median FiO2 prior to bronchoscopy (range)	0.5 (0.25-0.9)
Alive at end of study (remain in ICU)	17 (68%) 11
Median Duration of ventilation: days (range)	17 (2-42)
Median duration of ICU admission: days (range)	19 (2-44)
Immunocompromised* n(%)	6 (24%)

416

417 *Immunocompromised patients were defined as having active haematological malignancy,
418 neutropaenic malignancy, solid organ or bone marrow transplant and receipt of immunosuppressive
419 medication including corticosteroids for >1 week prior to hospital admission.

420

Patient	Sample	SARS-CoV-2	COVID-19	Organism with CT<32	Cultured Organism	VAP
Patient 1	1	POS	YES	<i>S. aureus</i>	No significant growth	YES
	2	POS	YES	<i>S. maltophilia</i>	No significant growth	YES
Patient 2	1	POS	YES	<i>H. influenzae</i>	No significant growth	YES
Patient 3	1	POS	YES	<i>K. pneumoniae, S. marcescens, E. coli S. epidermidis</i>	No significant growth	YES
Patient 4	1	POS	YES		No significant growth	NO
	2	POS	YES	<i>P. aeruginosa</i>	<i>P. aeruginosa</i>	YES
Patient 5	1	POS	YES	<i>HSV, S. epidermidis, C. albicans</i>	<i>C. albicans</i>	NO
	1	POS	YES	<i>S. aureus, S. epidermidis, Streptococcus spp</i>	<i>S. aureus</i>	YES
Patient 6	2	POS	YES	<i>S. aureus, E. faecium, S. marcescens</i>	<i>S. aureus</i>	YES
	3	POS	YES	<i>S. aureus, E. faecium, HSV</i>	<i>S. aureus, S. maltophilia</i>	YES
	1	POS	YES	<i>E. faecium, S. epidermidis</i>	Mixed upper resp. tract flora	NO
Patient 8	1	POS	YES	<i>E. faecium, C. albicans</i>	<i>C. albicans</i>	NO
Patient 9	1	POS	YES	<i>HSV, S. marcescens,</i>	<i>S. marcescens</i>	YES
	2	POS	YES	<i>E. faecium, S. marcescens</i>	No significant growth	YES
Patient 10	1	POS	YES	<i>K. pneumoniae</i>	No significant growth	YES
Patient 11	1	POS	YES		No significant growth	NO
Patient 12	1	POS	YES	<i>A. fumigatus, S maltophilia</i>	<i>S. maltophilia</i>	YES
Patient 13	1	POS	YES		No significant growth	NO
	1	POS	YES		No significant growth	NO
Patient 14	2	NEG	YES	<i>K. pneumoniae</i>	<i>K. pneumoniae</i>	YES
	3	NEG	YES	<i>K. pneumoniae</i>	<i>K. pneumoniae</i>	YES
Patient 15	1	NEG	NO	<i>C. albicans</i>	<i>C. albicans</i>	NO
Patient 16	1	NEG	NO		<i>E. coli</i>	YES
Patient 17	1	NEG	NO	<i>S. marcescens</i>	<i>Serratia marcescens</i>	YES
Patient 18	1	NEG	YES	<i>Streptococcus spp, E. Proteus , K. pneumoniae</i>	No significant growth	YES
Patient 19	1	NEG	YES	<i>E. faecium, E. coli</i>	<i>E. coli</i>	YES
Patient 20	1	NEG	YES	<i>Enterobacteriaceae</i>	No significant growth	YES
Patient 21	1	NEG	NO	<i>Streptococcus spp, H. influenzae</i>	No significant growth	YES
Patient 22	1	NEG	NO	<i>H. influenzae, Streptococcus spp, S. aureus</i>	No significant growth	YES
Patient 23	1	NEG	NO		No significant growth	NO
	2	NEG	NO		No significant growth	NO
Patient 24	1	NEG	NO	<i>HSV</i>	<i>HSV</i>	NO
	2	NEG	NO	<i>HSV</i>	No significant growth	NO
Patient 25	1	NEG	YES		No significant growth	NO

421 Table 2:

Figure 1

